Assessing and treating functional impairment in poststroke spasticity

Neurology

Volumn 80, Issue 3 SUPPL.2, 2013, Pages

  Sunnerhagen, Katharina S ^a   Olver, John ^b   Francisco, Gerard E ^c  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b MONASH UNIVERSITY   (Australia)

^c UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACLOFEN; BENZODIAZEPINE DERIVATIVE; BOTULINUM TOXIN A; BOTULINUM TOXIN B; CANNABINOID; DANTROLENE; GABAPENTIN; MUSCLE RELAXANT AGENT; PLACEBO; TIZANIDINE;

ATAXIA; CAREGIVER; CEREBROVASCULAR ACCIDENT; CLINICAL PRACTICE; CRYOTHERAPY; DRUG INDUCED HEADACHE; DRUG SAFETY; DYSESTHESIA; ELECTROACUPUNCTURE; ELECTROPHYSIOLOGY; EXTRACORPOREAL LITHOTRIPSY; FAINTNESS; FAMILY; FIBROSIS; HUMAN; LIVER TOXICITY; MEDICAL DECISION MAKING; MUSCLE CONTRACTION; MUSCLE STRETCHING; MUSCLE TONE; NUCLEAR MAGNETIC RESONANCE IMAGING; NYSTAGMUS; PAIN; POSTSTROKE SPASTICITY; PRIORITY JOURNAL; RANKIN SCALE; REVIEW; SOFT TISSUE FIBROSIS; SOMNOLENCE; SPASTICITY; TRANSCUTANEOUS NERVE STIMULATION;

EID: 84873646842     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/wnl.0b013e3182764aa2     Document Type: Review

References (77)

1. Barnes MP. An overview of the clinical management of spasticity. In: Barnes MP, Johnson GR, editors. Upper Motor Neurone Syndrome and Spasticity: Clinical Management and Neurophysiology, 2nd ed. New York: Cambridge University Press; 2008:1-8.
2. Malhotra S, Cousins E, Ward A, et al. An investigation into the agreement between clinical, biomechanical and neurophysiological measures of spasticity. Clin Rehabil 2008;22:1105-1115.
3. Malhotra S, Pandyan AD, Day CR, Jones PW, Hermens H. Spasticity, an impairment that is poorly defined and poorly measured. Clin Rehabil 2009;23:651-658.
4. Kelley RE, Borazanci AP. Stroke rehabilitation. Neurol Res 2009;31:832-840.
5. Brainin M, Norrving B, Sunnerhagen KS, et al. Poststroke chronic disease management: towards improved identification and interventions for poststroke spasticity-related complications. Int J Stroke 2011;6:42-46.
6. Lance JW. Symposium synopsis. In: Feldman RG, Young RR, Koella WP, editors. Spasticity: Disordered Motor Control. Miami: Year Book Medical Publishers; 1980:485-494.
7. Pandyan AD, Gregoric M, Barnes MP, et al. Spasticity: clinical perceptions, neurological realities and meaningful measurement. Disabil Rehabil 2005;27:2-6. (Pubitemid 40124834)
8. Decq P, Filipetti P, Lefaucher J-P. Evaluation of spasticity in adults. Oper Tech Neurosurg 2005;7:100-108. (Pubitemid 40725894)
9. Wissel J, Schelosky LD, Scott J, Christe W, Faiss JH, Mueller J. Early development of spasticity following stroke: a prospective, observational trial. J Neurol 2010; 257:1067-1072.
10. World Health Organization. International classification of functioning, disability and health (ICF). Available at: www. who.int/classifications/icf/en/. Accessed May 29, 2012.
11. Alibiglou L, Rymer WZ, Harvey RL, Mirbagheri MM. The relation between Ashworth scores and neuromechan-ical measurements of spasticity following stroke. J Neuroeng Rehabil 2008;5:18.
12. Gregson JM, Sharma AK. Measuring poststroke spasticity. Rev Clin Gerontol 2000;10:69-74. (Pubitemid 30598986)
13. Pandyan AD, Price CI, Barnes MP, Johnson GR. A bio-mechanical investigation into the validity of the modified Ashworth scale as a measure of elbow spasticity. Clin Re-habil 2003;17:290-293.
14. Blackburn M, van Vliet P, Mockett SP. Reliability of measurements obtained with the modified Ashworth scale in the lower extremities of people with stroke. Phys Ther 2002;82:25-34. (Pubitemid 34052113)
15. Gregson JM, Leathley M, Moore AP, Sharma AK, Smith TL, Watkins CL. Reliability of the Tone Assessment Scale and the modified Ashworth scale as clinical tools for assessing poststroke spasticity. Arch Phys Med Rehabil 1999;80:1013-1016. (Pubitemid 29439312)
16. Gracies JM, Burke K, Clegg NJ, et al. Reliability of the Tardieu Scale for assessing spasticity in children with cerebral palsy. Arch Phys Med Rehabil 2010;91:421-428.
17. Haugh AB, Pandyan AD, Johnson GR. A systematic review of the Tardieu Scale for the measurement of spas-ticity. Disabil Rehabil 2006;28:899-907.
18. Quinn TJ, Dawson J, Walters MR, Lees KR. Reliability of the modified Rankin Scale: a systematic review. Stroke 2009;40:3393-3395.
19. Kasner SE. Clinical interpretation and use of stroke scales. Lancet Neurol 2006;5:603-612. (Pubitemid 43867434)
20. Nakao S, Takata S, Uemura H, et al. Relationship between Barthel Index scores during the acute phase of rehabilitation and subsequent ADL in stroke patients. J Med Invest 2010;57:81-88.
21. Granger CV, Dewis LS, Peters NC, Sherwood CC, Barrett JE. Stroke rehabilitation: analysis of repeated Barthel index measures. Arch Phys Med Rehabil 1979;60:14-17. (Pubitemid 9101111)
22. Granger CV, Hamilton BB, Gresham GE. The stroke rehabilitation outcome study-Part I: general description. Arch Phys Med Rehabil 1988;69:506-509.
23. Granger CV, Hamilton BB, Gresham GE, Kramer AA. The stroke rehabilitation outcome study: Part II. Relative merits of the total Barthel index score and a four-item subscore in predicting patient outcomes. Arch Phys Med Rehabil 1989;70:100-103. (Pubitemid 19066469)
24. Dodds TA, Martin DP, Stolov WC, Deyo RA. A validation of the functional independence measurement and its performance among rehabilitation inpatients. Arch Phys Med Rehabil 1993;74:531-536. (Pubitemid 23141404)
25. Brashear A, Zafonte R, Corcoran M, et al. Inter-and intra-rater reliability of the Ashworth Scale and the Disability Assessment Scale in patients with upper-limb poststroke spasticity. Arch Phys Med Rehabil 2002;83:1349-1354.
26. Kanovský P, Slawek J, Denes Z, et al. Efficacy and safety of botulinum neurotoxin NT 201 in poststroke upper limb spasticity. Clin Neuropharmacol 2009;32:259-265.
27. Bowden M, Stokic DS. Clinical and neurophysiologic assessment of strength and spasticity during intrathecal baclofen titration in incomplete spinal cord injury: single-subject design. J Spinal Cord Med 2009;32:183-190.
28. Ploutz-Snyder LL, Clark BC, Logan L, Turk M. Evaluation of spastic muscle in stroke survivors using magnetic resonance imaging and resistance to passive motion. Arch Phys Med Rehabil 2006;87:1636-1642. (Pubitemid 44821076)
29. Turner-Stokes L. Goal attainment scaling (GAS) in rehabilitation: a practical guide. Clin Rehabil 2009;23:362-370.
30. Rosales RL, Chua-Yap AS. Evidence-based systematic review on the efficacy and safety of botulinum toxin-A therapy in post-stroke spasticity. J Neural Transm 2008; 115: 617-623.
31. Turner-Stokes L, Baguley IJ, De GS, et al. Goal attainment scaling in the evaluation of treatment of upper limb spasticity with botulinum toxin: a secondary analysis from a double-blind placebo-controlled randomized clinical trial. J Rehabil Med 2010;42:81-89.
32. Bhakta BB, Cozens JA, Chamberlain MA, Bamford JM. Impact of botulinum toxin type A on disability and career burden due to arm spasticity after stroke: a randomised double blind placebo controlled trial. J Neurol Neurosurg Psychiatry 2000;69:217-221. (Pubitemid 30466027)
33. Elovic EP, Brashear A, Kaelin D, et al. Repeated treatments with botulinum toxin type A produce sustained decreases in the limitations associated with focal upper-limb poststroke spasticity for caregivers and patients. Arch Phys Med Rehabil 2008;89:799-806. (Pubitemid 351602250)
34. McCrory P, Turner-Stokes L, Baguley IJ, et al. Botulinum toxin A for treatment of upper limb spasticity following stroke: a multi-centre randomized placebo-controlled study of the effects on quality of life and other person-centred outcomes. J Rehabil Med 2009;41:536-544.
35. Wissel J, Olver J, Sunnerhagen KS. Navigating the poststroke continuum of care. J Stroke Cerebrovasc Dis Epub 2011 Jul 4.
36. Smania N, Picelli A, Munari D, et al. Rehabilitation procedures in the management of spasticity. Eur J Phys Rehabil Med 2010;46:423-438.
37. Morris SL, Dodd KJ, Morris ME. Outcomes of progressive resistance strength training following stroke: a systematic review. Clin Rehabil 2004;18:27-39. (Pubitemid 38111282)
38. Woodford H, Price C. EMG biofeedback for the recovery of motor function after stroke. Cochrane Database Syst Rev 2007;2:CD004585.
39. Dimitrijevic MR. Clinical practice of functional electrical stimulation: from "Yesterday" to "Today." Artif Organs 2008;32:577-580.
40. Liu W, Mukherjee M, Sun C, Liu H, McPeak LK. Electro-acupuncture may help motor recovery in chronic stroke survivors: a pilot study. J Rehabil Res Dev 2008;45:587-595.
41. Godfrey SB, Schabowsky CN, Holley RJ, Lum PS. Hand function recovery in chronic stroke with HEXORR robotic training: a case series. Conf Proc IEEE Eng Med Biol Soc 2010;2010:4485-4488.
42. Gracies JM, Nance P, Elovic E, McGuire J, Simpson DM. Traditional pharmacological treatments for spasticity. Part II: general and regional treatments. Muscle Nerve Suppl 1997;6:S92-S120. (Pubitemid 128753040)
43. Herman R, Freedman W, Mayer N. Neurophysiologic mechanisms of hemiplegic and paraplegic spasticity: implications for therapy. Arch Phys Med Rehabil 1974;55:338-343.
44. Lapeyre E, Kuks JB, Meijler WJ. Spasticity: revisiting the role and the individual value of several pharmacological treatments. Neuro Rehabilitation 2010;27:193-200.
45. Hesse S, Werner C. Poststroke motor dysfunction and spasticity: novel pharmacological and physical treatment strategies. CNS Drugs 2003;17:1093-1107. (Pubitemid 38021395)
46. Kamen L, Henney HR III, Runyan JD. A practical overview of tizanidine use for spasticity secondary to multiple sclerosis, stroke, and spinal cord injury. Curr Med Res Opin 2008;24:425-439. (Pubitemid 351294392)
47. Wagstaff AJ, Bryson HM. Tizanidine: a review of its pharmacology, clinical efficacy and tolerability in the management of spasticity associated with cerebral and spinal disorders. Drugs 1997;53:435-452. (Pubitemid 27117363)
48. Formica A, Verger K, Sol JM, Morralla C. Gabapentin for spasticity: a randomized, double-blind, placebo-controlled trial [in Spanish]. Med Clin (Barc) 2005;124:81-85. (Pubitemid 40293161)
49. Pooyania S, Ethans K, Szturm T, Casey A, Perry D. A randomized, double-blinded, crossover pilot study assessing the effect of nabilone on spasticity in persons with spinal cord injury. Arch Phys Med Rehabil 2010;91:703-707.
50. Smith PF. New approaches in the management of spastic-ity in multiple sclerosis patients: role of cannabinoids. Ther Clin Risk Manag 2010;6:59-63.
51. Dvorak EM, Ketchum NC, McGuire Jr. The underutili-zation of intrathecal baclofen in poststroke spasticity. Top Stroke Rehabil 2011;18:195-202.
52. Zhao F, Li P, Chen SR, Louis CF, Fruen BR. Dantrolene inhibition of ryanodine receptor Ca21 release channels: molecular mechanism and isoform selectivity. J Biol Chem 2001;276:13810-13816.
53. Chan CH. Dantrolene sodium and hepatic injury. Neurology 1990;40:1427-1432. (Pubitemid 20291654)
54. Utili R, Boitnott JK, Zimmerman HJ. Dantrolene-associ-ated hepatic injury: incidence and character. Gastroenter-ology 1977;72:610-616. (Pubitemid 8097598)
55. Elovic EP, Esquenazi A, Alter KE, Lin JL, Alfaro A, Kaelin DL. Chemodenervation and nerve blocks in the diagnosis and management of spasticity and muscle over-activity. PM R 2009;1:842-851.
56. Simon O, Yelnik AP. Managing spasticity with drugs. Eur J Phys Rehabil Med 2010;46:401-410.
57. Sheean G. Botulinum toxin treatment of adult spasticity: a benefit-risk assessment. Drug Saf 2006;29:31-48. (Pubitemid 43213894)
58. Marciniak C. Poststroke hypertonicity: upper limb assessment and treatment. Top Stroke Rehabil 2011;18:179-194.
59. FDA approves Botox to treat spasticity in flexor muscles of the elbow, wrist and fingers. FDA News Release. Available at: www.fda.gov/NewsEvents/ Newsroom/PressAnnouncement-s/2010/ucm203776.htm. Accessed May 29, 2012.
60. ® (onabotulinumtoxinA) Full Prescribing Information. Irvine, CA: Allergan, Inc.; 2011.
61. Bakheit AM, Zakine B, Maisonobe P, et al. The profile of patients and current practice of treatment of upper limb muscle spasticity with botulinum toxin type A: an international survey. Int J Rehabil Res 2010;33:199-204.
62. ®): in dystonias and focal spasticity. Drugs 2011;71: 1043-1058.
63. ®): the first botulinum toxin drug free of complexing proteins. Eur J Neurol 2012;19:385-389.
64. Brashear A, Gordon MF, Elovic E, et al. Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after a stroke. N Engl J Med 2002;347:395-400. (Pubitemid 34851831)
65. Kaji R, Osako Y, Suyama K, Maeda T, Uechi Y, Iwasaki M. Botulinum toxin type A in post-stroke upper limb spasticity. Curr Med Res Opin 2010;26:1983-1992.
66. Simpson DM, Alexander DN, O'Brien CF, et al. Botuli-num toxin type A in the treatment of upper extremity spasticity: a randomized, double-blind, placebo-controlled trial. Neurology 1996;46:1306-1310. (Pubitemid 26159292)
67. Yablon SA, Brin MF, Van Denburgh AM, et al. Dose response with onabotulinumtoxinA for post-stroke spastic-ity: a pooled data analysis. Mov Disord 2011;26:209-215.
68. Mancini F, Sandrini G, Moglia A, Nappi G, Pacchetti C. A randomised, double-blind, dose-ranging study to evaluate efficacy and safety of three doses of botulinum toxin type A (Botox) for the treatment of spastic foot. Neurol Sci 2005;26:26-31. (Pubitemid 40723938)
69. Simpson DM, Gracies JM, Yablon SA, Barbano R, Brashear A. Botulinum neurotoxin versus tizanidine in upper limb spasticity: a placebo-controlled study. J Neurol Neurosurg Psychiatry 2009;80:380-385.
70. Bakheit AM, Thilmann AF, Ward AB, et al. A randomized, double-blind, placebo-controlled, dose-ranging study to compare the efficacy and safety of three doses of botu-linum toxin type A (Dysport) with placebo in upper limb spasticity after stroke. Stroke 2000;31:2402-2406.
71. Burbaud P, Wiart L, Dubos JL, et al. A randomised, double blind, placebo controlled trial of botulinum toxin in the treatment of spastic foot in hemiparetic patients. J Neurol Neurosurg Psychiatry 1996;61:265-269. (Pubitemid 26293721)
72. ®) in the treatment of spastic equinovarus deformity after stroke. Cerebrovasc Dis 2003;15:289-300. (Pubitemid 36438734)
73. Kanovský P, Slawek J, Denes Z, et al. Efficacy and safety of treatment with incobotulinum toxin A (botulinum neurotoxin type A free from complexing proteins; NT 201) in post-stroke upper limb spasticity. J Rehabil Med 2011;43:486-492.
74. Brashear A, McAfee AL, Kuhn ER, Fyffe J. Botulinum toxin type B in upper-limb poststroke spasticity: a double-blind, placebo-controlled trial. Arch Phys Med Rehabil 2004;85:705-709. (Pubitemid 38857904)
75. Gormley ME Jr, O'Brien CF, Yablon SA. A clinical overview of treatment decisions in the management of spastic-ity. Muscle Nerve Suppl 1997;6:S14-S20. (Pubitemid 128753036)
76. Olver J, Esquenazi A, Fung VS, Singer BJ, Ward AB. Botu-linum toxin assessment, intervention and aftercare for lower limb disorders of movement and muscle tone in adults: international consensus statement. Eur J Neurol 2010;17(suppl 2): 57-73.
77. Lai JM, Francisco GE, Willis FB. Dynamic splinting after treatment with botulinum toxin type-A: a randomized controlled pilot study. Adv Ther 2009;26:241-248.